Recent studies have also shown that disrupting the interaction between β-catenin and BCL9 can also inhibit oncogenic WNT/β-catenin activity [85,86] and ST316, a novel peptide antagonist of β-catenin that inhibits the interaction with BCL9 and has recently entered the path of clinical trials (NCT05848739) and its activity is investigated in several cancer types including melanoma. The gene discussed is BCL9; the disease is cancer.